arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2005-11-3-201-203arthyper-1024Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESЭффективность и безопасность нового генерика аторвастатина - препарата Тулип® - у больных с гиперлипидемиейThe effectiveness and safety of Tulip in patients with hyperlipidemiaМоисееваО. М.MoiseevaO. M.noemail@neicon.ruКарелкинаЕ. В.KarelkinaYe. V.noemail@neicon.ruФГБУ «Федеральный медицинский исследовательский центр имени В.А. Алмазова» Минздрава РоссииРоссия200528062005113201203Copyright © Моисеева О.М., Карелкина Е.В., 20052005Моисеева О.М., Карелкина Е.В.Moiseeva O.M., Karelkina Y.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1024

Цель исследования - оценить гиполипидемическую эффективность и безопасность применения нового генерика аторвастатнна - препарата Тулип, зарегистрированного в России компанией "LEК", Словения. Материалы и методы. В открытое проспективное неконтролируемое исследование включены 40 пациентов в возрасте 57,3±1,2 года с гиперлипидемией. Результаты. Из 40 больных, включенных в настоящее исследование 19 (47,5 %) достигли целевого уровня холестерина (ХС) липопротеидов низкой плотности (ЛПНП) уже к 4-й неделе терапии на фоне приема 10 мг Тулипа, а 7 (17,5 %) пациентов к 8-й неделе при приеме 20 мг препарата в целом по группе на фоне терапии Тулипом целевого уровня ХС ЛПНП достигли 65 % пациентов. В процессе лечения содержание общего ХС в сыворотке крови к 8-й неделе терапии снизилось на35,6 % ХС липопротеидов очень низкой плотности на 44,6 %, ХС липопротеидов высокой плотности (ЛПВП) на 39,8 %, триглицеридов на 40,9 %, отмечена тенденция к увеличению уровня ХС ЛПВП в сыворотке крови. Выраженный гиполипидемический эффект лекарственного препарата Тулип не сопровождался повышением трансаминаз (АСТ, АЛТ) и креатинфосфокиназы. Выводы: Выраженный гиполипидемический эффект препарата Тулип, сопоставимы с оригинальным аторвастатином, имеет несомненную привлекательность для практического использования в России в связи с меньшими экономическими затратами на его приобретение. Препарат Тулип продемонстрировал свою безопасность и хорошую переносимость.

The purpose of the study was to evaluate the hypolipidemic effectiveness and safety of use of Tulip, a novel atorvastatin generic agent, registered by LEK, Slovenia, in Russia. Materials and methods. The open prospective uncontrolled study covered in hyperlipidemic patients aged 57,3±1,2 years. Of the 40 patients included into the present study, 19 (47.5 %) achieved the target level of low-density lipoprotein (LDL) cholesterol just by week 4 of therapy when 10 mg of Tulip was used and 7 (17,5 %) patients did by week 8 when 20 mg of the drug was given. As a whole, 65 % of patients achieved the target level of DLD cholesterol in the Tulip group. By treatment week 8, there were35,6; 44,6; 39,8 and 40,9 % decreases in the serum content of total cholesterol, very low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides, respectively. The serum level of LDL cholesterol tended to increase. The pronounced hypolipidemic effect of Tulip was not attended by increases in transaminases (aspartate aminotransferase and alanine aminotranferase) and creatinine phosphokinase. Conclusions. The marked hypolipidemic effect of Tulip, which is comparable with that of the original drug atorvastatin, is unquestionable to he attractable for practical use in Russia due to its inexpensive cost. Tulip has demonstrated to be safe and well tolerated.

ReferencesWilson P.W.F., D'Agostino R.B., Levy D. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.Wilson P.W.F., D'Agostino R.B., Levy D. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.Stamler J., Wentworth D., Neaton J.D. for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 1986; 256: 2823-8.Stamler J., Wentworth D., Neaton J.D. for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 1986; 256: 2823-8.Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention trial results. I: Reduction in the incidence of а пошит heart disease. JAMA 1984; 251: 351-64Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention trial results. I: Reduction in the incidence of а пошит heart disease. JAMA 1984; 251: 351-64Lipid Research Clinics Program. The Lipid Research Coronary Primary Prevention Trial results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.Lipid Research Clinics Program. The Lipid Research Coronary Primary Prevention Trial results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22.National Cholesterol Education Program (NCEP) Expert Panel on Deteiction. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III). Third Report of the Notional Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.National Cholesterol Education Program (NCEP) Expert Panel on Deteiction. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III). Third Report of the Notional Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.Low M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2005; 326; 1423-9.Low M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2005; 326; 1423-9.LaRosa J.C. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001: 88: 291-3.LaRosa J.C. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001: 88: 291-3.Halcox J.P.J., Deanfield J.E. Beyond the Laboratory Clinical Implications for Statin Pleiotropy. Circuiation 2004; 109 (suppl. II): II-42-II48.Halcox J.P.J., Deanfield J.E. Beyond the Laboratory Clinical Implications for Statin Pleiotropy. Circuiation 2004; 109 (suppl. II): II-42-II48.Ford E.S., Mokdad A.H., Giles W.H. et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among 15 adults: findings from the National Health and Nutrition Examination surrey. 1999 to 2000. Circulation 2003: 107: 2185-9.Ford E.S., Mokdad A.H., Giles W.H. et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among 15 adults: findings from the National Health and Nutrition Examination surrey. 1999 to 2000. Circulation 2003: 107: 2185-9.Белоусов Ю.Б., Грацианский Н.А., Бекетов А.А. Оценка фармакоэкономической эффективности аторвастатина (липрилара) при вторичной профилактике ИБС. Качествен. клин. практ. 2002: 1: 62-70.Белоусов Ю.Б., Грацианский Н.А., Бекетов А.А. Оценка фармакоэкономической эффективности аторвастатина (липрилара) при вторичной профилактике ИБС. Качествен. клин. практ. 2002: 1: 62-70.McNamara J.R., Cole T.G., Contois J.H. et al. Immunoseparation method for measuring low density lipoprotein cholesterol directly from serum evaluated. Clin Cbem 1995; 41: 232-40.McNamara J.R., Cole T.G., Contois J.H. et al. Immunoseparation method for measuring low density lipoprotein cholesterol directly from serum evaluated. Clin Cbem 1995; 41: 232-40.Sever P.S., Dahlof B. et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo Scandinavian Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomised controlled trial, Lancet 2003; 361: 1149-58.Sever P.S., Dahlof B. et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo Scandinavian Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomised controlled trial, Lancet 2003; 361: 1149-58.La Rosa J.C., Grundy S.W., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.La Rosa J.C., Grundy S.W., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.Cannon C.P., Brawnwald E., McCabe C.H. et al. Pravastatin or Atorvastatin Evaluation and Injection Therapy-Trombosis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid loitering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.Cannon C.P., Brawnwald E., McCabe C.H. et al. Pravastatin or Atorvastatin Evaluation and Injection Therapy-Trombosis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid loitering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.Sacks F.M., Tonkin A.M., Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000: 102: 1893-900.Sacks F.M., Tonkin A.M., Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000: 102: 1893-900.Nissen S.E., Tuzcu E.M., Schoenbagen P. et al. Effect of intensive compared with moderate lipid loitering therapy on progression of coronary atherosclerosis. JAMA 2004; 291: 1071-80.Nissen S.E., Tuzcu E.M., Schoenbagen P. et al. Effect of intensive compared with moderate lipid loitering therapy on progression of coronary atherosclerosis. JAMA 2004; 291: 1071-80.Grandy S.M., Cleeman J.I., Bairey Merz C.N. et al. Implication of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidlines. Circulation 2004; 110: 227-39.Grandy S.M., Cleeman J.I., Bairey Merz C.N. et al. Implication of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidlines. Circulation 2004; 110: 227-39.

The authors declare that there are no conflicts of interest present.